What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent

Area of Science:

• Radiology
• Medical Imaging
• Pharmacovigilance

Background:

• Ferumoxytol (Feraheme) is increasingly considered for MR imaging despite a 2015 FDA boxed warning.
• Radiologists are exploring ferumoxytol as an alternative or supplement to gadolinium-based contrast agents.
• The study investigates ferumoxytol safety for MR imaging post-label change.

Purpose of the Study:

• To assess ferumoxytol safety for MR imaging at a single center.
• To evaluate the impact of the Feraheme label change on its use as an off-label MR contrast agent.

Main Methods:

• Retrospective analysis of ferumoxytol-related adverse events during CNS MR imaging.
• Evaluation of 671 MR studies in 331 patients who received ferumoxytol via rapid bolus injections.
• Correlation of adverse event risk with patient demographics and medical history.

Main Results:

• No anaphylactic, life-threatening, or fatal adverse events were observed.
• 10.6% of patients experienced mild (grade 1-3) adverse events, including hypertension, nausea, diarrhea, and headache.
• A history of allergies was associated with a higher risk of adverse events (14.61% vs. 7.51%).

Conclusions:

• Ferumoxytol demonstrated a low frequency of mild adverse events, consistent with previous research.
• No serious adverse events were recorded, suggesting rarity with proper precautions.
• Ferumoxytol may serve as a valuable MR imaging agent when used cautiously, adhering to FDA guidelines.